MAH & portfolio ownership
Product selection, authorization strategy and lifecycle stewardship.
↗
NUEVA CAPITALPHARMA
Partner with Nueva ↗Nueva Capital Pharma connects qualified international manufacturers with Egypt through MAH, regulatory, commercial representation, medical engagement and regional market-development solutions.
A selective, compliance-led operating model integrating MAH stewardship, regulatory execution, medical engagement, commercialization and regional development.
Product selection, authorization strategy and lifecycle stewardship.
↗Dossier assessment, submission coordination and market readiness.
↗A structured local platform for international manufacturers.
↗Credible engagement with healthcare professionals, hospitals and clinics.
↗Pre-launch planning, distributor selection and measurable execution.
↗Controlled pathways from Egypt into MENA and Africa.
↗Our Egypt-centred model combines local regulatory understanding with international operating standards—creating a structured pathway for registration, localization, commercialization and responsible regional growth.
Every opportunity is evaluated for regulatory feasibility, documentation quality, market need, competitive intensity and regional potential.
Controlled expansion through qualified local partners, disciplined country selection, regulatory readiness and distributor performance governance across the GCC, Levant, North Africa and selected Sub-Saharan markets.
Explore regional strategy →01 · Priority Arab marketsJordan · Saudi Arabia · UAE · Oman · Bahrain · Kuwait · Iraq
02 · North AfricaLibya · Sudan · Morocco · Algeria · Tunisia
03 · Sub-Saharan AfricaKenya · Ethiopia · Nigeria · Ghana · Tanzania · Rwanda